Literature DB >> 12006681

Leukodystrophy in children: a pictorial review of MR imaging features.

Jung-Eun Cheon1, In-One Kim, Yong Seung Hwang, Ki Joong Kim, Kyu-Chang Wang, Byung-Kyu Cho, Je Geun Chi, Chong Jai Kim, Woo Sun Kim, Kyung Mo Yeon.   

Abstract

Dysmyelinating diseases, or leukodystrophies, encompass a wide spectrum of inherited neurodegenerative disorders affecting the integrity of myelin in the brain and peripheral nerves. Most of these disorders fall into one of three categories-lysosomal storage diseases, peroxisomal disorders, and diseases caused by mitochondrial dysfunction-and each leukodystrophy has distinctive clinical, biochemical, pathologic, and radiologic features. Magnetic resonance (MR) imaging has become the primary imaging modality in patients with leukodystrophy and plays an important role in the identification, localization, and characterization of underlying white matter abnormalities in affected patients. MR imaging has also been extensively used to monitor the natural progression of various white matter disorders and the response to therapy. Although the MR imaging features of leukodystrophy are often nonspecific, systematic analysis of the finer details of disease involvement may permit a narrower differential diagnosis, which the clinician can then further refine with knowledge of patient history, clinical testing, and metabolic analysis. Copyright RSNA, 2002

Entities:  

Mesh:

Year:  2002        PMID: 12006681     DOI: 10.1148/radiographics.22.3.g02ma01461

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  36 in total

1.  Radiological clue to diagnosis of Canavan disease.

Authors:  Priya Sreenivasan; K K Purushothaman
Journal:  Indian J Pediatr       Date:  2012-06-02       Impact factor: 1.967

2.  [Metabolic disorders with typical alterations in MRI].

Authors:  M Warmuth-Metz
Journal:  Radiologe       Date:  2010-09       Impact factor: 0.635

3.  Imaging of CNS myelin by positron-emission tomography.

Authors:  Bruno Stankoff; Yanming Wang; Michel Bottlaender; Marie-Stephane Aigrot; Frederic Dolle; Chunying Wu; Douglas Feinstein; Guo-Feng Huang; Frank Semah; Chester A Mathis; William Klunk; Robert M Gould; Catherine Lubetzki; Bernard Zalc
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

4.  Toward a better understanding of brain lesions during metachromatic leukodystrophy evolution.

Authors:  A Martin; C Sevin; C Lazarus; C Bellesme; P Aubourg; C Adamsbaum
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

5.  Neurological picture. Tigroid and leopard skin pattern of dysmyelination in metachromatic leucodystrophy.

Authors:  R Nandhagopal; S G Krishnamoorthy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

6.  A study of the reproducibility and etiology of diffusion anisotropy differences in developmental stuttering: a potential role for impaired myelination.

Authors:  M D Cykowski; P T Fox; R J Ingham; J C Ingham; D A Robin
Journal:  Neuroimage       Date:  2010-05-13       Impact factor: 6.556

7.  Thickening of the optic nerves in metachromatic leucodystrophy: A new MRI finding.

Authors:  Dylan Roi; Kshitij Mankad; Marios Kaliakatsos; Maureen Cleary; Adnan Manzur; Felice D'Arco
Journal:  Neuroradiol J       Date:  2016-02-25

8.  Multiple cranial nerve enhancement: a new MR imaging finding in metachromatic leukodystrophy.

Authors:  Antonio C M Maia; Antônio J da Rocha; Carlos J da Silva; Sérgio Rosemberg
Journal:  AJNR Am J Neuroradiol       Date:  2007 Jun-Jul       Impact factor: 3.825

Review 9.  Tools for diagnosis of leukodystrophies and other disorders presenting with white matter disease.

Authors:  Adeline Vanderver
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

10.  Biotin-responsive basal ganglia disease: neuroimaging features before and after treatment.

Authors:  H Kassem; A Wafaie; S Alsuhibani; T Farid
Journal:  AJNR Am J Neuroradiol       Date:  2014-05-08       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.